NCT04573023进行中（未招募）3 期
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 86
- 试验地点
- 54
- 主要终点
- Change in levels of cerebrospinal fluid heparan sulfate from baseline (Cohort A)
研究概览
简要总结
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •* A patient who voluntarily signs an Institutional Review Board or Independent Ethics Committee-approved written informed consent form. If the patient is aged under 18 years (aged under 16 years in the UK) at the time of enrollment or willingness to participate in the study cannot be confirmed due to MPS II-related intellectual disability, the patient's legally acceptable representative (e.g., his/her parents or guardians) may sign the informed consent on behalf of the patient. Written informed assent should be obtained from the patient, wherever possible.
- •* Patients with confirmed diagnosis of MPS II
- •* Naïve patients or patients who are receiving stable enzyme replacement therapy with idursulfase for more than 12 weeks before starting administration of JR-141 or idursulfase for this study.
- •* Patients or patients whose partners are of child-bearing potential agree to use a medically accepted, highly effective method of contraception being use of condoms from the time of informed consent.
- •\ * Patients aged 36-42 months old at the time of ICF signing: patients must have a standard score measured by the BSID-III of 85 or less at screening.
- •* Patients aged 43-71 months old at the time of ICF signing: patients must EITHER have (1) A DQ measured by BSID-III of 20 to 85 at screening OR (2) A composite standard score on NVI measured by KABC-II of 85 or less at screening (only who can perform KABC-II)
- •* Patients aged 30-35 months old at the time of randomization and who are judged as having the severe phenotype by the Expert Board.
- •\ * Patients 6 years of age or older at the time of ICF signing and whose IQ are 70 and higher.
- •* Enrollment of subjects in Cohort B is contingent on the availability in that country of a validated country-specific version of the test (either WISC-V, WAIS-IV, or T.O.V.A.).
- •* Attenuated patients with 1 SD deficiency in the omission errors or variability domains of the T.O.V.A..
- •* Patients or patients whose female partners are of child-bearing potential i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile, agree to use a medically accepted, highly effective method of contraception, from the time of informed consent. The method of contraception must be used during the study until 90 days for male subjects, and 30 days for female subjects after the final study intervention administration.
- •* For subjects with hearing impairment requiring hearing aid(s), every effort has been made to encourage compliance with the use of functioning hearing aid(s) before baseline neurocognitive assessments, and parent/legally acceptable representative or subject agrees to encourage wearing them during the study and on neurocognitive testing days.
排除标准
- •A patient with a history of HSCT with successful engraftment.
- •A patient who has received gene therapy treatment at any point.
- •A patient who is judged by the principal investigator or sub-investigator as being unable to undergo lumbar puncture, including those who have difficulties in taking position for lumbar puncture due to joint contracture or those who are likely to experience breathing difficulties during the lumbar puncture process.
- •A patient who is enrolled in another clinical study that involves clinical investigations or use of any investigational product (drug or device) within 4 months before obtaining informed consent.
- •Unable to comply with the protocol as determined by the principal investigator or subinvestigator.
- •Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity including anesthesia or hypersensitivity to any component of JR-
- •A patient who has a known or suspected local or general infection or is at risk of abnormal bleeding due to medical conditions or therapies.
- •A patient who has documented mutation of other genes, including loci adjacent to the IDS gene that are known to be associated with developmental delay, seizures, or other significant CNS disorders.
- •A patient who has documented loss of activity of sulfatases other than IDS.
- •A patient who has had a ventriculoperitoneal shunt placed or any other brain surgery, or has a clinically significant ventriculoperitoneal shunt malfunction within 30 days of screening.
- •A patient who is full time employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members.
- •A patient who otherwise is judged by the principle investigator or sub-investigator to be ineligible to participate in the study.
- •The subject has a positive pregnancy test or is breastfeeding at screening or randomization.
- •[Only in France]
- •Persons deprived of their liberty by a judicial or administrative decision, according to article L.1121-6 the Public Health Code (Code de la santé publique), adults who are the subject of a measure of legal protection or unable to express their consent according to article L. 1121-8 of the Code de la santé publique)
研究组 & 干预措施
JR-141 2.0 mg/kg/week
Experimental
干预措施: JR-141 (Drug)
Rescue arm
Other
干预措施: JR-141 or Idursulfase (Drug)
administered as the standard of care: idursulfase (ELAPRASE®)
Other
standard of care-controlled study
干预措施: Idursulfase (Drug)
结局指标
主要结局
Change in levels of cerebrospinal fluid heparan sulfate from baseline (Cohort A)
时间窗: Baseline to Week 53
Change in the raw scores of cognitive testing measured from baseline (BSID-III) (Cohort A)
时间窗: Baseline to Week 105
次要结局
- For regions other than US: Change in the age equivalent scores of cognitive testing measured from baseline (BSID-III or KABC-II) (Cohort A)(Baseline to Week 105)
- For regions other than US: Change in the age equivalent scores of adaptive behavior measured from baseline (VABS-II) (Cohort A)(Baseline to Week 105)
- For the US: Change in the raw scores of adaptive behavior measured from baseline (VABS-II) (Cohort A)(Baseline to Week 105)
- For all regions: Relative change in liver volume relative to body weight from baseline (Cohort A and Cohort B)(Baseline to Week 53)
- For all regions: Relative change in spleen volume relative to body weight from baseline (Cohort A and Cohort B)(Baseline to Week 53)
研究者
研究点 (54)
Loading locations...
相似试验
已完成
1 期
A Study of JR-171 in Patients With Mucopolysaccharidosis IMucopolysaccharidosis INCT04227600JCR Pharmaceuticals Co., Ltd.18
已完成
2 期
A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)Mucopolysaccharidosis IINCT03359213JCR Pharmaceuticals Co., Ltd.18
进行中（未招募）
2 期
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type IIMucopolysaccharidosis IINCT04348136JCR Pharmaceuticals Co., Ltd.27
已完成
2 期
A Study of JR-141 in Patients With Mucopolysaccharidosis IIMucopolysaccharidosis IINCT03568175JCR Pharmaceuticals Co., Ltd.28
已完成
1 期
A Study of JR-171 in Patients With Mucopolysaccharidosis Type IJPRN-jRCT2080225015JCR Pharmaceuticals Co., Ltd,19